MTOR and primitive neuroectodermal tumor: Recently, everolimus (mammalian target of rapamycin [mTOR] inhibitor) yielded a longer progression-free survival (PFS) and a survival benefit of 6.3 months compared with placebo which brought a hope for advanced PNET patients [37, 53].